An Adaptive,Dose-Finding,Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics
Free accessMeeting reportFirst published online November, 2012
An Adaptive,Dose-Finding,Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics
Dulaglutide (dula, LY2189265) is a once-weekly glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus. An adaptive, dose-finding, inferentially seamless phase 2/3 study was designed to support the development of this novel diabetes therapeutic. The study is divided into two stages based on two randomization schemes: A Bayesian adaptive scheme (stage 1) and a fixed scheme (stage 2). Stage 1 of the trial employs an adaptive, dose-finding design to lead to a dula dose-selection decision or early study termination due to futility. If dose selection occurs, the study proceeds to stage 2 to allow continued evaluation of the selected dula doses. At completion, the entire study will serve as a confirmatory phase 3 trial. The final study design is discussed, along with specifics pertaining to the actual execution of this study and selected baseline characteristics of the participants.
SchmidtWESiegelEGCreutzfeldtW.Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia.1985;28 (9): 704–7.
2.
GentilellaRBianchiCRossiARotellaCM, Exenatide: A review from pharmacology to clinical practice. Diabetes Obes Metab.2009;11 (6): 544–56.
3.
HansenKBKnopFKHolstJJVilsbollT.Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract.2009;63: 1154–60.
4.
OrskovCWettergrenAHolstJJ, Secretion of the incretin hormones glucagon like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol.1996;31 (7): 665–70.
5.
GlaesnerWVickAMMillicanREllisBTschangSHTianYBokvistKBrennerMKoesterAPorksenNEtgenGBumolT.Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev.2010;26 (4): 287–96.
6.
BarringtonPChienJYTibaldiFShowalterHDSchneckKEllisB.LY2189265, a long-acting glucagon-like peptide 1 analogue, showed a dose dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab.2011;13 (5): 434–43.
7.
BarringtonPChienJYShowalterHDSchneckKCuiSTibaldiFEllisBHardyTA, A 5 week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide 1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab.2011;13 (5): 426–43.
8.
GustavsonSMChenDSomayajiVHudsonKBaltrukonisDJSinghJBoydenTLCalleRA, Effects of a long-acting GLP-1 mimetic (PF 04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab2011;13 (11): 1056–8.
9.
KotharePALinnebjergHIsakaYUenakaKYamamuraAYeoKPde la PeñaATengCHMaceKFinemanMShigetaHSakataYIrieS.Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol.2008;48 (12): 1389–99.
10.
HalbirkMNørrelundHMøllerNHolstJJSchmitzONielsenRNielsen-KudskJENielsenSSNielsenTTEiskjaerHBøtkerHEWiggersH.Cardiovascular and metabolic effects of 48-hour glucagon-like peptide-1 infusion in compensated chronic heart failure patients. Am J Physiol Heart Circ Physiol.2010;298 (3): H1096–1102.
11.
FariesD.Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat.1994;4 (2): 147–64.
12.
GalloPChuang-SteinCDragalinVGaydosBKramsMPinheiroJ.Adaptive designs in clinical drug development — An executive summary of the PhRMA working group. J. Biopharm Stat.2006;16: 275–83.
13.
GalloPKramsM.PhRMA working group on adaptive designs: Introduction to the full white paper. Drug Inf J.2006;40 (4): 421–3.
14.
SkrivanekZBerrySBerryDChienJGeigerMJAndersonJHJrGaydosB. Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): Statistical design and simulations. J Diabetes Sci Technol.2012;6 (6): 1305–18.
15.
SpencerKColvinKBrauneckerBBrackmanMRipleyJHinesPSkrivanekZGaydosBGeigerMJ, Operational challenges and solutions with implementation of an adaptive, seamless phase 2/3 study. J Diab Sci Tech.2012;6 (6): 1296–1304.
16.
FoxKBorerJSCammAJDanchinNFerrariRSendonJL LopezStegPGTardifJCTavazziLTenderaM.Resting heart rate in cardiovascular disease. J Am Coll Cardiol.2007;50 (9): 823–30.
17.
CookSTogniMSchaubMCWenaweserPHessOM, High heart rate: A cardiovascular risk factor?Eur Heart J.2006;27 (20): 2387–93.
18.
LewingtonSClarkeRQizilbashNPetoRCollinsR, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet.2002;360 (9349): 1903–13.
19.
[FDA] Food and Drug Administration. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008a. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed on July 29, 2012.
20.
GrunbergerGChangAGarcia-SoriaGBotrosFTBsharatRMilicevicZ.Monotherapy with the once weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med.2012; 1464–5491.
